Abstract Purpose: We previously discovered an extracellular matrix (ECM) gene cluster associated with resistance to first-line tamoxifen therapy of patients with metastatic breast cancer. In this study, we determined whether the six individual ECM genes [collagen 1A1 (COL1A1), fibronectin 1 (FN1), lysyl oxidase (LOX), secreted protein acidic cysteine-rich (SPARC), tissue inhibitor of metalloproteinase 3 (TIMP3), and tenascin C (TNC)] were associated with treatment response, prognosis, or both. Experimental Design: In 1,286 primary breast tumors, mRNA expression (quantitative realtime PCR) was related to clinicopathologic factors and disease outcome in univariate and multivariate analysis including traditional factors. Results:TIMP3, FN1, LOX, and SPARC expression levels (continuous variables) were significantly associated with distant metastasis-free survival (MFS) in 680 lymph node^negative untreated patients (P < 0.03). Using a calculated linear prognostic score, these patients were evenly divided into five prognostic groups with a significant difference in 10-year MFS of f40% between the two extreme prognostic groups. Furthermore, high TNC expression as continuous variable was associated with (a) shorter MFS in 139 estrogen receptor^positive and lymph node^positive patients who received adjuvant tamoxifen therapy (hazard ratio, 1.53; P = 0.001), and (b) no clinical benefit (odds ratio, 0.81; P = 0.035) and shorter progression-free survival (hazard ratio, 1.19; P = 0.002) in 240 patients in whom recurrence was treated with tamoxifen as first-line monotherapy. These results were also significant in multivariate analyses. Conclusion: FN1, LOX, SPARC, and TIMP3 expression levels are associated with the prognosis of patients with breast cancers, whereasTNC is associated with resistance to tamoxifen therapy. Further validation and functional studies are necessary to determine the use of these ECM genes in decisions regarding treatment and whether they can serve as targets for therapy.
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One of the major challenges in oncology is the individualization of treatment. For patients with localized breast cancer, prognostic profiles that discriminate between patients at low and high risk to develop distant metastases, are crucial to avoid overtreatment or undertreatment, respectively. In addition to prognostic factors, there is a great need for predictive factors that enable the identification of breast cancer patients who are likely to benefit from a certain therapy. One of the drugs most often used in breast cancer treatment is the selective estrogen receptor modulator tamoxifen. Although f75% of the breast tumors express the estrogen receptor (ER), approximately half of these ER-positive breast cancer patients fail to benefit from tamoxifen, whereas those initially responding to tamoxifen will eventually develop resistance. Improved insight into the factors determining sensitivity is therefore urgently needed. In a previous study in patients with advanced disease, we revealed a discriminatory signature of 81 genes associated with resistance to first-line tamoxifen treatment (1) . Functional annotation of the signature genes showed that 9% of these genes were involved in extracellular matrix (ECM) formation. Furthermore, clustering analysis of the 81 genes revealed that the genes involved in ECM formation showed a similar expression pattern and therefore clustered together in a socalled ECM gene cluster. This ECM gene cluster included, collagen 1A1 (COL1A1), fibronectin 1 (FN1), lysyl oxidase (LOX), secreted protein acidic cysteine-rich (SPARC), tissue inhibitor of metalloproteinase 3 (TIMP3), and tenascin C (TNC).
The ECM acts as a substrate to which cells can adhere and serves as a reservoir for growth factors. As a result, the ECM, for instance via binding to integrins, has a major role in regulating both cell proliferation and migration, and consequently, metastasis. Malignant breast tumors are characterized by the loss of normal tissue architecture and cell-ECM interactions (2) . This is illustrated by the changes in the constitution of the ECM during epithelial to mesenchymal transformation, a process in which cells lose their strong intercellular adhesion, which is an early manifestation of malignant development of epithelial cells (3, 4) . During this transformation, FN1, h1-integrin, and vimentin are upregulated whereas E-cadherin expression is down-regulated. The ECM plays a role in proliferation and metastasis and has therefore been associated with the prognosis of patients with (breast) cancer. For instance, ECM genes have been part of a general metastasis predictive signature including COL1A1 (5), as well as in breast cancer -specific prognostic signatures (6 -8) . In addition, patients with breast cancer could be divided into four subgroups with different clinical outcomes using the expression levels of only ECM genes with SPARC being one of the top genes (9) .
Remarkably, in addition to a putative role in prognosis, the results from our above-described molecular profiling study suggested a relation between ECM and response to tamoxifen therapy (1) . Several studies have suggested that the adhesion of tumor cells to the ECM could play a role in therapy resistance, the so-called cell adhesion -mediated drug resistance. Cell adhesion -mediated drug resistance was initially observed by Durand et al. in V79 Chinese hamster cells grown in spheroids due to spinning of the culture flask which prevented adhesion (10) . The outer layer of these spheroids was shown to be more resistant to radiation (10) as well as to the drug etoposide (11) when compared with cells grown as a monolayer.
Besides spheroid culturing, cell adhesion -mediated drug resistance was also observed when cells were cultured in monolayers. Several studies have shown that adhesion of hematopoietic or lung cancer cell lines to the ECM proteins FN1, laminin, or collagen yields resistance to a number of drugs like etoposide, melphalan, mitoxantrone, cisplatin, and cyclophosphamide as well as radiation (12, 13) . Furthermore, this effect was shown to be dependent on the interaction of the ECM proteins with the cell membrane receptor h1-integrin (12, 13). The exact mechanism by which ECM proteins confer resistance to antitumor therapies, however, remains to be established.
In this study (reported according to the REMARK recommendations; ref. 14), we examined whether the genes in our previously discovered ECM gene cluster were associated with the natural course of the disease, i.e., prognosis and/or clinical benefit from tamoxifen therapy. We measured the expression of the six ECM genes with quantitative real-time PCR (qRT-PCR) in 1,286 primary breast cancer specimens and determined the association with patient and tumor characteristics, survival of the untreated patient, and clinical benefit from as well as progression-free survival after tamoxifen treatment.
Patients and Methods
Patients. This study was approved by the medical ethics committee of the Erasmus MC (Rotterdam, the Netherlands; MEC 02.953). This study, in which coded tumor tissues were used, was done in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands. 1 The study includes breast tumor tissue specimens from 1,683 female patients with primary operable breast cancer who entered the clinic between 1979 and 1996. Frozen tumor samples were processed and detailed clinical follow-up information from these breast cancer patients was available. Follow-up, tumor staging, and type of response to therapy was defined by standard International Union Against Cancer (Geneva, Switzerland) classification criteria (15) . The cutpoint to classify primary breast tumors as ER and/or progesterone receptor (PgR) -positive was 10 fmol/mg cytosolic protein. ERBB2 mRNA levels, determined by RT-PCR, 2 displayed a clear bimodal distribution, therefore, the cutpoint for being ERBB2 -amplified or not was determined similar as described for microarray data (for a detailed description, see Van Agthoven et al. 2 and Urban et al.; ref. 16) . Tumor specimens of the following patients were excluded from analysis: (a) patients that showed distant metastasis within the first month after surgery, (b) patients with unknown lymph node status or ER protein status, (c) when <30% of epithelial tumor cells were present in the tumor specimens, and (d) if the specimens had a poor RNA quality (17) . After applying the exclusion criteria, tumor specimens of 1,286 patients (76%) were analyzed for COL1A1, FN1, LOX, SPARC, TIMP3, and TNC expression with qRT-PCR (Fig. 1) .
From these 1,286 patients (for clinicopathologic details, see Table 1 ), 571 patients (44%) underwent breast-conserving lumpectomy and 715 patients (56%) underwent modified mastectomy. Additional radiotherapy was given to 923 of the 1,286 patients (72%). The median followup time of the 684 patients alive was 92 months (ranging from 3 to 248 months). Distant metastasis occurred in 644 of the 1,286 patients.
Four hundred and ten patients (32%; all lymph node -positive) were treated with adjuvant systemic therapy; 190 patients (46%) received hormonal therapy, 204 (50%) received chemotherapy (137 CMF, 67 anthracyclin containing), and 16 (4%) received both hormonal and chemotherapy. Of the 1,080 patients (84%) who had not received adjuvant endocrine therapy, 523 patients developed a distant metastasis. Two hundred and forty (46%) of these patients who had an ERpositive tumor received first-line tamoxifen monotherapy. Based on the type of response, these patients were divided into having clinical benefit or not having clinical benefit from first-line tamoxifen therapy. No clinical benefit was observed in 90 of these patients, of whom 73 showed progressive disease (30%) and 17 patients (7%) who showed stable disease for V6 months. One hundred and fifty (63%) of these 240 patients had experienced a clinical benefit from first-line tamoxifen monotherapy, of whom 9 patients (4%) had a complete remission, 35 patients (15%) showed a partial remission, and 106 patients (44%) showed stable disease at >6 months.
RNA isolation and qRT-PCR. Tissue processing, RNA isolation, cDNA synthesis, and qRT-PCR were done as described previously by Sieuwerts et al. (17) . In brief, total RNA was extracted from the whole tissue section using RNABee (Campro) and 5 Ag of total RNA was reverse-transcribed using oligo(dT) [12] [13] [14] [15] [16] [17] [18] and random hexamer primers. qRT-PCR was done in an ABI Prism 7700 Sequence Detection System (Applied Biosystems) using both the Assay-on-Demand kits from Applied Biosystems and the intron-spanning forward and reverse primer combinations. The commercially available Assay-on-Demand kits (Applied Biosystems) were used for COL1A1 (Hs00164004_m1), FN1 (Hs00415006_m1), LOX (Hs00184700_m1), SPARC (Hs00277762_m1), TIMP3 (Hs00165949_m1), and TNC (Hs001115664_m1). Primer sequences for the three reference (housekeeping) genes (i.e., porphobilinogen deaminase, hypoxanthineguanine phospho-ribosyltransferase, and h2-microglobulin) ER and PgR have been previously described (17) , as well as the primer sequences for epidermal growth factor receptor (EGFR) and ERBB2 (18) . PCR reactions were done on cDNA synthesized from 5 to 15 ng of total RNA in a final volume of 25 AL as previously described (17) . After 40 rounds of amplification, quantitative values were obtained from the threshold cycle (Ct) at which the increase in SYBR green or TaqMan probe fluorescent signal (associated with an exponential increase of PCR products) reached the fixed threshold value of 0.02, which was in all cases, at least 10-fold the SD of the background signal. To enable a comparison of the levels of specific mRNAs in different samples, the expression levels were normalized against the average expression levels of the three reference (housekeeping) genes as follows (17): mRNA target = 2 (mean Ct housekeeping genes -mean Ct target) . Data analysis and statistics. The relationship of the expression level of COL1A1, FN1, LOX, SPARC, TIMP3, and TNC with patient and tumor characteristics were investigated using nonparametric methods, i.e., Spearman rank correlations for continuous variables and Wilcoxon rank-sum or Kruskal-Wallis test for ordered variables. The patient and tumor characteristics were used as grouping variables. Cox univariate and multivariate regression analyses were used to determine the hazard ratios (HR) for overall survival (OS), distant metastasis-free survival (MFS), progression-free survival (PFS), and post-relapse survival (PRS) as a function of the expression level of each gene. We defined PRS as the duration of survival from the start of first-line tamoxifen monotherapy of the distant metastasis. In multivariate analysis, Cox proportional hazards regression models were applied to determine if the prognostic or predictive value as a function of the expression levels of each gene were independent of the traditional factors. Logistic regression analysis was done to calculate the odds ratio that defines the relation between expression levels and clinical benefit from therapy. Both HR and odds ratio were calculated with Box-Cox transformed variables (to reduce skewness of the distribution) and were represented with their 95% confidence intervals (95% CI).
When the test for trend for a continuous variable with respect to a specific end point (e.g., MFS, OS, and PFS) was statistically significant, a cutpoint was considered justified. To define cutpoints, isotonic regression analysis was used to find the points at which the monotonic relationship between the measured level and the HR showed a distinct change (19) . The cutpoint with the largest statistically significant change in HR corrected for multiple testing was used.
When the continuous variable was more significantly associated with a specific end point (e.g., MFS, OS, and PFS) compared with any cutpoint, the continuous expression was used for further (survival) analysis. For further analysis, we combined the prognostic value of the (continuous expression levels of the) ECM genes that were significant in univariate analysis by calculating two prognostic scores as described previously (20) . The first one was calculated by combining the estimates of the Cox regression analysis for these ECM genes and the second prognostic score was calculated by combining the estimates of the Cox regression analysis for the ECM genes as well as those for the prognostic clinicopathologic factors (20) . Both prognostic scores were used to classify patients into risk groups using the 20, 40, 60, and 80 percentiles of the prognostic score as cutpoints. The resulting five risk groups are visualized by Kaplan-Meier survival curves and the log-rank P value for trend analysis is given in the figure.
Computations were done with the STATA statistical package, release 10 (STATA, Corp.). All P values were two-sided, and P < 0.05 was considered statistically significant.
Results
Association with clinicopathologic factors. We determined the ECM gene expression in 1,286 primary breast carcinomas from female patients diagnosed with breast cancer from 1979 to 1996. As expected, based on our previous expression profiling study, the gene expression levels of all six ECM genes were significantly correlated with each other (n = 1,286; P < 0.0001). The Spearman rank correlation of TNC with the other genes ranged from 0.25 to 0.50, whereas the correlation coefficients of FN1, LOX, SPARC, TIMP3, and COL1A1 with each other were higher and ranged from 0.59 to 0.84. Interestingly, EGFR and ERBB2 mRNA expression was also significantly positively correlated with all six ECM genes and this was significant after Table 1 shows median expression levels of the six ECM genes and their relation with patient and tumor characteristics. After Bonferroni correction, ER and PgR protein expression levels were significantly positively correlated with TIMP3 (r s , 0.16 and 0.08, respectively), whereas ER was negatively correlated with LOX (r s , -0.14) and TNC (r s , -0.21). FN1, LOX, SPARC, and TIMP3, but not TNC and COL1A1, show a strong association with nodal status. Interestingly, TIMP3 was the only gene that showed an association with all clinocopathologic factors tested that are known to be associated with prognosis.
ECM gene expression and prognosis. To determine whether there is a relation between the ECM gene expression levels and the natural course of the disease, and thus, prognosis (independent of therapy response), we analyzed 680 lymph node -negative (LNN) patients who did not receive any adjuvant systemic treatment (Fig. 1) . Of these 680 patients, 265 developed a distant metastasis during the follow-up period. When analyzed univariately as continuous variables, high FN1, LOX, and SPARC expression levels were significantly associated with a shorter MFS ( Fig. 2 ; Supplementary Table S1) as well as a shorter OS. The hazards ratios for OS were 1.14 (95% CI, 1.02-1.27; P = 0.016; for FN1); 1.20 (95% CI, 1.00-1.43; P = 0.048; for LOX); and 1.14 (95% CI, 1.00-1.29; P = 0.05; for SPARC). High TIMP3 expression was associated with a prolonged MFS ( Fig. 2 ; Supplementary Table S1) but there was no significant association with OS (HR, 0.89; 95% CI, 0.79-1.01; P = 0.07). In addition, when added as continuous variables to the base model including all traditional factors, FN1, LOX, and SPARC contributed significantly to the model for MFS ( Fig. 2 ; Supplementary  Table S1 ) and FN1 also contributed to the model for OS (HR, 1.16; 95% CI, 1.04-1.29; P = 0.011).
Considering that the continuous variables for LOX, SPARC, and TIMP3 were more significantly associated with MFS compared with any other cutpoint, the continuous expressions of FN1, LOX, SPARC, and TIMP3 were used for further (survival) analysis. Subsequently, we combined the prognostic value of the FN1, LOX, SPARC, and TIMP3 continuous expression levels by calculating two prognostic scores as described previously (20) . The first one was calculated by combining the estimates of the Cox regression analysis for these ECM genes and the second prognostic score was calculated by combining the estimates of the Cox regression analysis for the ECM genes as well as those for the prognostic clinicopathologic factors (20) . Both prognostic scores were used to classify patients into five risk groups using as cutpoints the 20, 40, 60 and 80 percentiles of the prognostic score. The resulting five risk groups are visualized by Kaplan-Meier survival curves ( Fig. 3A and B) . The log-rank trend analysis showed that for both prognostic scores, the survival curves for the five risk groups are sequential and differ significantly from each other (Fig. 3A and B, P < 0.001). The 10-year MFS for risk groups 1, 2, 3, 4, and 5 were, respectively, 72% (95% CI, 61-81%), 63% (95% CI, 53-71%), 63% (95% CI, 54-71%), 53% (95% CI, 43-81%), and 37% (95% CI, 29-46%) for the analysis based on FN1, LOX, SPARC, and TIMP3 expression levels. The 10-year MFS was 72% (95% CI, 61-81%), 71% (95% CI, 61-78%), 61% (95% CI, 52-69%), 51% (95% CI, 42-59%), and 34% (95% CI, 26-43%) for the analysis based on FN1, LOX, SPARC, and TIMP3 expression levels as well as the prognostic clinicopathologic factors. This results in a significant difference of 35% and 38%, respectively, between the poor (risk group 5) and the good prognostic group (risk group 1). ECM gene expression and survival after tamoxifen therapy and response. The relation between the ECM gene expression levels and MFS after adjuvant tamoxifen treatment was evaluated in 139 ER-positive primary breast carcinomas from lymph node -positive patients (Fig. 1) . When analyzed as continuous variables, high TNC, FN1, or LOX expression levels were significantly associated with a shorter MFS ( Fig. 2 ; Supplementary Table S2) . When added to the traditional prognostic factors of the base multivariate model, only TNC contributed significantly to this model ( Fig. 2 ; Supplementary  Table S2) .
To determine whether the observed association of these genes with MFS was due to an association with prognosis and/ or clinical benefit from tamoxifen therapy, we evaluated the ECM gene expression levels in 240 ER-positive primary breast carcinomas from patients whose relapse was treated with firstline tamoxifen monotherapy (Fig. 1) . These patients did not receive (neo-)adjuvant endocrine treatment and were therefore tamoxifen-naBve. For these 240 patients, the type of response to first-line tamoxifen therapy could be determined according to the standard International Union Against Cancer classification criteria. When analyzed as a continuous variable in univariate analysis, high TNC expression level was significantly associated with a shorter PFS ( Fig. 2; Supplementary Table S3 ), PRS (HR, 1.15; 95% CI, 1.02-1.30; P = 0.018), as well as treatment failure (odds ratio, 0.81; 95% CI, 0.66-0.99; P = 0.035). When added to the traditional factors in a multivariate model, TNC Table S3) and PRS (HR, 1.17; 95% CI, 1.03-1.34; P = 0.017) but not for clinical benefit (odds ratio, 0.89; 95% CI, 0.71-1.12; P = 0.31).
A cutpoint was defined to dichotomize TNC expression levels in the patients who received adjuvant tamoxifen therapy, which was significantly associated with a shorter MFS in univariate analysis ( Fig. 2; Supplementary Table S2 ). Furthermore, another cutpoint was defined to dichotomize TNC expression levels in the patients with advanced disease treated with first-line tamoxifen, which was significantly associated with a shorter PFS in univariate analysis in multivariate analysis ( Fig. 2; Supplementary Table S3 ). Thus, TNC was significantly associated with MFS of adjuvant tamoxifen-treated patients, and in addition to clinical benefit and PFS of relapsed patients who received first-line tamoxifen therapy.
Discussion
In our previous expression profiling study, we discovered an ECM gene cluster of six genes associated with response to tamoxifen. In the current study, the mRNA expression of these six genes was measured in 1,286 primary breast cancer specimens in order to determine whether the individual ECM genes were associated with the natural course of the disease, i.e., prognosis (independent of therapy response), clinical benefit from tamoxifen therapy, or both.
The tumor expression levels of four of the six ECM genes, FN1, LOX, SPARC, and TIMP3, were associated with MFS of Fig. 2 . Association of ECM gene expression levels with survival. Multivariate model for distant MFS includes age, menopausal status, tumor size, lymph node status, grade, continuous log ER, and log PgR mRNA levels. Multivariate model for PFS includes age, menopausal status, disease-free interval, site of relapse, continuous log ER, and log PgR mRNA levels.
lymph node -negative patients who received no adjuvant systemic therapy. Therefore, this duration of MFS (i.e., prognosis) was solely influenced by the natural course of the disease. This analysis showed that high FN1, LOX, and SPARC expression levels were associated with a shorter MFS. This association was independent of the traditional prognostic factors. In contrast, high TIMP3 expression was associated with a prolonged MFS, however, this was not independent of the traditional prognostic factors. TIMP3 was the only gene associated with all of the tested clinicopathologic factors, which explains its insignificance in the multivariate analysis.
Because FN1, LOX, SPARC, as well as TIMP3 were associated with the prognosis of LNN patients, we calculated a prognostic score based on the regression coefficients of FN1, LOX, SPARC, and TIMP3 expression levels with or without the prognostic clinicopathologic factors. Based on this score, we evenly divided the 680 patients with LNN into five risk groups. This resulted in a difference in 10-year MFS between the two extreme prognostic groups (risk group 1 versus risk group 5) of 33% when the prognostic score was based on FN1, LOX, SPARC, and TIMP3 expression levels alone, and 38% when the prognostic clinicopathologic factors were included in the prognostic score.
Further validation of the stratification of the patients based on the expression of FN1, LOX, SPARC, and TIMP3 (on the mRNA and protein level) in addition to the prognostic clinicopathologic factors is necessary to reveal whether it might aid in the identification of different prognostic groups of patients with LNN. Furthermore, functional studies could discover whether the ECM proteins might form targets for therapy to prevent the dissemination of cancer cells.
Previously, an association with poor prognosis of breast cancer patients was reported for a high expression level of FN1 (21 -23) , LOX (24, 25) , and SPARC (26, 27) . Interestingly, a low TIMP3 expression level was associated with the shorter relapse-free survival of 107 breast cancer patients treated with adjuvant endocrine therapy (28) . Based on our above-described results, this is most likely due to a relation with prognosis independent of response to treatment. This is further supported by the fact that TIMP3 was not associated with the type of response (and PFS) in 240 patients whose relapse was treated with first-line tamoxifen monotherapy. Figure 4A depicts the location and interaction of the ECM proteins in the extracellular space. When looking at the function of these proteins, the association of FN1, LOX, SPARC, and TIMP3 with prognosis is not surprising. The involvement in migration processes such as embryogenesis, wound healing, and metastasis of cancer cells has been shown for FN1 (29) and LOX (reviewed in ref. 25) . Furthermore, FN1 expression is up-regulated during epithelial-to-mesenchymal transition, which is an early event in the malignant transformation accompanied by a reduced adhesion of the tumor cells. SPARC is a classic adhesion-modulating ECM protein which regulates ECM production and causes de-adhesion (30) . In contrast, TIMP3 is an inhibitor of matrix metalloproteinases, which are known to be involved in metastasis by degradation of the ECM. Overexpression of TIMP3 has been shown to counteract primary tumor growth, angiogenesis, tumor invasion, and the development of metastases (summarized in ref. 28) .
In addition to its prognostic value in untreated LNN patients, high expression levels of FN1 and LOX were also associated with a shorter MFS after adjuvant tamoxifen treatment of ERpositive lymph node -positive patients. However, the duration of MFS is also influenced by the benefit from adjuvant therapy. Therefore, the relation of FN1 and LOX with prognosis independent of therapy response (as observed in these LNN patients), is most likely causing the observed association with MFS after adjuvant treatment. This is further supported by the fact that FN1 and LOX were not associated with clinical benefit from first-line tamoxifen monotherapy in the 240 relapsed patients.
The fifth gene from the ECM cluster and one of the genes examined in this study, COL1A1, was not associated with prognosis, MFS after adjuvant tamoxifen therapy, or clinical benefit from tamoxifen in the advanced setting.
Also, the sixth ECM gene, TNC, was not associated with prognosis in the LNN-untreated patients (independent of therapy response). However, a high TNC expression level was associated with a shorter MFS after adjuvant tamoxifen treatment as well as a lack of clinical benefit from first-line tamoxifen monotherapy and a shorter PFS and PRS in the 240 relapsed patients. This suggests that TNC is not associated with prognosis but is indeed associated with clinical benefit from tamoxifen therapy.
TNC is an adhesion-modulating ECM protein and is highly expressed in the microenvironment of most solid tumors including breast cancer. The protein has been shown to be involved in a wide variety of processes such as proliferation, epithelial-to-mesenchymal transition, tumor cell migration, invasion, and metastasis (reviewed in ref. 31 ). Furthermore, splice variants are known to show different expressions in malignant versus normal breast tissue (32) and could also have a different functional role. A miRNA that regulates TNC expression, miR-335, was recently discovered (33) . The association of this miRNA, as well as the TNC splice variants, with tamoxifen response will be the subject for further investigations.
There are two possible mechanisms that may account for the observed association between TNC expression and tamoxifen resistance (Fig. 4B) . First, high TNC expression could be a (indirect) marker for a defective estrogen response pathway. We observed a significant inverse correlation between TNC mRNA expression and ER protein expression (r s = -0.21, P < 0.0001) and, similar to this, an inverse correlation between TNC protein and ER protein expression was observed by others (22, 34, 35) . This might suggest that TNC expression is repressed by ER. On the other hand, one study showed that tenascin expression in the tumor was not affected by ovariectomy or antiestrogen treatment of rats with 7,12-dimethylbenz(a)anthraceneinduced mammary tumors (36) . This indicates that the inverse correlation could be not a direct effect of estrogen but might be a more downstream effect or a side effect of, for instance, an ER-associated phenotype. Nevertheless, TNC could still be an indirect marker for a defective estrogen response pathway. Thus, the high TNC expression observed in the ER-positive tamoxifen-resistant breast carcinomas could be indicative for a defective estrogen pathway, which would render the cells unresponsive to endocrine treatments such as tamoxifen.
The second mechanism involves the generation of a proliferative signal that causes the tumor cells to become independent of estrogen-induced growth stimulus, and thus, resistant to endocrine treatment. There are several ways in which TNC could play a role in the generation of this proliferative signal. As discussed in the Introduction, the interaction of ECM proteins (e.g., TNC) with integrin could result in direct activation of growth factor receptors or in a growth stimulus similar to that induced by growth factor signaling (37, 38) . Interestingly, besides binding to integrin, TNC contains epidermal growth factor -like domains that can bind and activate the EGFR (39, 40). Indeed, we observed a significant positive correlation of TNC and EGFR mRNA expression (r s = 0.32, P < 0.0001). It has been suggested that (the low-affinity) binding of TNC to EGFR would result in a similar activation of cell migration as epidermal growth factor itself, but only in a very weak activation of proliferation (40) . We hypothesize that the TNC-induced clustering of EGFR on the cell surface together with the binding of ECM protein (e.g., TNC) to integrin could result in integrin-mediated activation of the nearby EGFR. This would result in a proliferative signal that could render the cells estrogen-independent, and thus, resistant to endocrine therapy. Indeed, Jones et al. observed a similar interaction in vascular smooth muscle cells (41) . They showed that the interaction of integrin with TNC alters the shape of the cells and increases EGFR clustering and epidermal growth factordependent growth.
Functional studies have to elucidate whether the relation between TNC and tamoxifen resistance, possibly via integrin and/or EGFR signaling, is causal or only associative. The involvement of integrin and/or EGFR should be assessed by looking at downstream signaling molecules and their phosphorylation status as well as inhibition or down-regulation of integrin and/or EGFR by treating with inhibitors or small interfering RNA. When integrin and/or EGFR signaling are indeed involved, it is worthwhile to assess whether or not these patients benefit from treatment with h1-integrin blocking antibodies and/or EGFR inhibitors such as erlotinib, gefitinib, lapatinib, or cetuximab, which are already used in clinical practice.
In conclusion, we have shown that expression of ECM genes is associated with the prognosis of patients with LNN breast cancer (FN1, LOX, SPARC, and TIMP3) as well as clinical benefit from endocrine treatment (TNC). Further validation and functional studies are necessary to determine the use of these ECM genes in decisions regarding treatment and whether they can serve as targets for therapy. Moreover, the relation of TNC induced integrin-signaling and/or EGFR-signaling with tamoxifen resistance deserves further study.
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